Skip to main content
. 2022 Oct 4;20:454. doi: 10.1186/s12967-022-03667-2

Fig. 2.

Fig. 2

General comparison of immune markers between primary tumors and liver metastases (A Foxp3, B IFN-γ, C CD56, D CD66b, E CD163). (*p < 0.05, **p < 0.01, ***p < 0.001)